List With HCPCS Codes For COVID-19 Infusion Therapy

The HCPCS codes for COVID-19 Infusion Therapy (Q0220-Q0249) cover various injections used for pre-exposure prophylaxis and treatment of COVID-19 in individuals with compromised immune systems or severe adverse reactions to COVID-19 vaccines.

1. HCPCS Code Q0220

HCPCS Q0220 describes the injection of tixagevimab and cilgavimab, given as pre-exposure prophylaxis for certain adults and pediatric individuals with no known exposure to SARS-CoV-2, who have compromised immune systems or cannot receive COVID-19 vaccines due to severe adverse reactions.

2. HCPCS Code Q0221

HCPCS Q0221 describes the injection of a higher dosage of tixagevimab and cilgavimab, given as pre-exposure prophylaxis for certain adults and pediatric individuals with no known exposure to SARS-CoV-2, who have compromised immune systems or cannot receive COVID-19 vaccines due to severe adverse reactions.

3. HCPCS Code Q0222

HCPCS Q0222 describes the injection of bebtelovimab, used for the treatment of COVID-19.

4. HCPCS Code Q0240

HCPCS Q0240 describes the injection of casirivimab and imdevimab, given as a combined therapy for the treatment of COVID-19.

5. HCPCS Code Q0243

HCPCS Q0243 describes the injection of a higher dosage of casirivimab and imdevimab, given as a combined therapy for the treatment of COVID-19.

6. HCPCS Code Q0244

HCPCS Q0244 describes the injection of a lower dosage of casirivimab and imdevimab, given as a combined therapy for the treatment of COVID-19.

7. HCPCS Code Q0245

HCPCS Q0245 describes the injection of bamlanivimab and etesevimab, used for the treatment of COVID-19.

8. HCPCS Code Q0247

HCPCS Q0247 describes the injection of sotrovimab, used for the treatment of COVID-19.

9. HCPCS Code Q0249

HCPCS Q0249 describes the injection of tocilizumab, used for the treatment of hospitalized adults and pediatric patients with COVID-19 who require supplemental oxygen, mechanical ventilation, or ECMO, and are receiving systemic corticosteroids.